Profiling the fungal microbiome after fecal microbiota transplantation for graft-versus-host disease: Insights from a phase 1 interventional study Journal Article
| Authors: | van Lier, Y. F.; Rolling, T.; Armijo, G. K.; Zhai, B.; Haverkate, N. J. E.; Meijer, E.; Nur, E.; Blom, B.; Peled, J. U.; van den Brink, M. R. M.; Hohl, T. M.; Hazenberg, M. D.; Markey, K. A. |
| Article Title: | Profiling the fungal microbiome after fecal microbiota transplantation for graft-versus-host disease: Insights from a phase 1 interventional study |
| Abstract: | Disruption of the intestinal bacterial microbiota is frequently observed in the context of allogeneic hematopoietic cell transplantation (HCT) and is particularly pronounced in patients who develop graft-versus-host disease (GVHD). Donor fecal microbiota transplantation (FMT) restores gut microbial diversity and reduces GVHD in HCT recipients. The composition of the intestinal fungal community in patients with GVHD, and whether fungal taxa are transferred during FMT are currently unknown. We performed a secondary analysis of our clinical trial of FMT in patients with steroid-refractory GVHD with a focus on the mycobiota. We characterized the fecal mycobiota of 17 patients and healthy FMT donors using internal transcribed spacer amplicon sequencing. The donor who pro-vided the majority of FMT material in our study represents an n-of-one study of the intestinal flora over time. In this donor, mycobiota composition fluctuated over time while the bacterial microbiota remained stable over 16 months. Fungal DNA was detected more frequently in baseline stool samples from patients with steroid-refractory GVHD than in patients with steroid-dependent GVHD. We could detect fungal taxa in the majority of samples but did not see evidence of mycobiota transfer from donor to recipient. Our study demonstrates the feasibility of pro-filing the mycobiota alongside the more traditional bacterial microbiota, establishes the methodology, and pro-vides a first insight into the mycobiota composition of patients with GVHD.(c) 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved. |
| Keywords: | transplantation; disease; risk-factors; candida-albicans; marrow; recipients; allogeneic hematopoietic cell; acute gvhd; fecal microbiota transplantation; acute graft-versus-host; mycobiome; mycobiota |
| Journal Title: | Transplantation and Cellular Therapy |
| Volume: | 29 |
| Issue: | 1 |
| ISSN: | 2666-6375 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-01-01 |
| Start Page: | 63.e1 |
| End Page: | 63.e5 |
| Language: | English |
| ACCESSION: | WOS:000971813700001 |
| DOI: | 10.1016/j.jtct.2022.10.011 |
| PROVIDER: | wos |
| PMCID: | PMC10190111 |
| PUBMED: | 36280104 |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work